Table 1 Clinical characteristics of patients in our cohort (n = 82)
From: Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury
| Characteristic | No. of patients (%) |
|---|---|
| Mean age (standard deviation) | 57 years (14) |
| Male sex | 54 (66) |
| Race/ethnicity | |
| White | 63 (77) |
| Black | 7 (9) |
| Hispanic | 9 (11) |
| Other | 3 (4) |
| Baseline risk factors | |
| History of smoking | 35 (43) |
| Alcohol consumption | 35 (43) |
| Type II diabetes mellitus | 21 (26) |
| Drug allergy | 51 (62) |
| Prior history of pancreatitis | 7 (9) |
| Pancreatic metastasis | 11 (13) |
| Cancer type | |
| Melanoma | 30 (37) |
| Genitourinary | 24 (29) |
| Lung, head and neck | 11 (13) |
| Gastrointestinal | 5 (6) |
| Other solid tumors | 5 (6) |
| Hematologic malignancies | 7 (9) |
| Cancer stagea | |
| Stage III | 3 (4) |
| Stage IV | 72 (96) |
| Median number of immune checkpoint inhibitor doses (interquartile range) | 4 (1-25) |
| Checkpoint inhibitor type | |
| CTLA-4 monotherapy | 12 (15) |
| PD-1/L1 monotherapy | 53 (65) |
| Combination therapyb | 17 (21) |
| Other immune-related adverse events | |
| Gastrointestinal | 27 (33) |
| Hepatic | 17 (21) |
| Dermatologic | 13 (16) |
| Endocrine | 7 (9) |
| Pulmonary | 5 (6) |
| Other | 6 (7) |